地塞米松植入物治疗非感染性葡萄膜炎:单中心经验
这项前瞻性单中心干预性临床试验于2010年2月至2015年3月纳入76例非感染性葡萄膜炎伴黄斑囊样水肿和/或玻璃体炎患者,共109眼接受298次700μg玻璃体内地塞米松植入物注射。中央视网膜厚度从基线465μm显著降至1、3、6个月时的318、342、388μm(P<0.001),视力与玻璃体混浊评分亦改善;眼压出现一过性升高,眼部并发症可逆(白内障形成除外)。
要点
- 109眼接受298次700μg地塞米松植入物注射,44%的眼注射超过3次。
- 中央视网膜厚度从基线465μm显著降至1、3、6个月时的318、342、388μm(P<0.001)。
- 1个月时44%的眼玻璃体混浊评分显著降低,眼压出现一过性升高(1个月P<0.001,3个月P=0.001)。
核心结论
- 反复较长疗程使用地塞米松植入物治疗非感染性葡萄膜炎,单用或联合其他治疗,可改善中央视网膜厚度、最佳矫正视力和玻璃体混浊。
- 基础疾病和伴随的系统治疗似乎影响整体治疗获益。
- 眼部并发症可逆并可通过局部治疗处理,但白内障形成除外。
研究设计与样本
- 前瞻性、单中心、干预性临床试验,时间为2010年2月至2015年3月。
- 纳入非感染性葡萄膜炎伴黄斑囊样水肿和/或玻璃体炎的患者,共76例患者109眼,接受298次700μg玻璃体内地塞米松植入物(Ozurdex)注射。
- 注射后1、3、6个月安排随访,记录最佳矫正视力、中央视网膜厚度、玻璃体混浊评分、眼压和不良事件。
主要发现
- 中央视网膜厚度从基线465μm显著降至1、3、6个月时的318、342、388μm(P<0.001)。
- 接受第2、3、4次地塞米松植入物注射的眼呈现相似趋势。
- 特发性葡萄膜炎和结节病患者从地塞米松植入物中获益良好;未接受系统治疗以及接受抗代谢药和环孢素A的患者整体获益最大。
- 1个月时44%的眼玻璃体混浊评分显著降低。
- 1、3、6个月时最佳矫正视力提高超过3行的眼分别为31%至37%、26%至39%、8%至32%。
关键数值与推荐
- 主要结局指标为中央视网膜厚度降低,次要结局指标为最佳矫正视力改善和玻璃体混浊降低。
- 76例患者中52例为女性(68%),全部参与者平均年龄57岁(范围24至88岁)。
- 44%的眼注射超过3次地塞米松植入物;12、18、24个月平均注射次数分别为1.54±0.5、1.98±0.84、2.46±1.1(标准差)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To report the effectiveness of repeated intravitreal dexamethasone (DEX) inserts in noninfectious uveitis patients. DESIGN: Prospective, single-center, interventional clinical trial between February 2010 and March 2015. PARTICIPANTS: Patients with noninfectious uveitis with cystoid macular edema and/or vitreitis. METHODS: Patients were treated with a 700-μg intravitreal DEX insert (Ozurdex; Allergan, Inc., Irvine, CA). Follow-up visits were scheduled 1, 3, and 6 months after injection. Best-corrected visual acuity (BCVA), central retinal thickness (CRT), vitreous haze (VH) score, intraocular pressure (IOP), and adverse events were recorded. MAIN OUTCOME MEASURES: Primary outcome was the reduction of CRT. Secondary outcome was the improvement in BCVA and reduction of VH. RESULTS: In total, 109 eyes of 76 patients received 298 DEX inserts. Fifty-two patients were women (68%). The mean age of all participants was 57 years (range, 24-88 years). More than 3 DEX inserts were injected into 44% of eyes. Mean number of injections were 1.54±0.5 (standard deviation [SD]), 1.98±0.84, and 2.46±1.1 over 12, 18, and 24 months, respectively. Central retinal thickness decreased significantly (P < 0.001) from 465 μm at baseline to 318, 342, and 388 μm after 1, 3, and 6 months, respectively. Similar trends were seen in eyes receiving a second, third, and fourth DEX insert. Patients with idiopathic uveitis and sarcoidosis benefited well from DEX inserts. The greatest overall benefit was achieved in patients with no systemic treatment and patients receiving antimetabolites and cyclosporin A. A significant VH score reduction was documented in 44% of eyes after 1 month. A gain of more than 3 lines in BCVA was recorded in 31% to 37%, 26% to 39%, and 8% to 32% of eyes after 1, 3, and 6 months, respectively. A transient rise in mean IOP after 1 month (P < 0.001) and after 3 months (P = 0.001) was seen. CONCLUSIONS: The repeated longer-term administration of DEX inserts in noninfectious uveitis patients, either alone or in combination with other therapies, led to improved CRT, BCVA, and VH. Underlying diseases and concomitant systemic therapy seem to have an impact on overall treatment benefit. Ocular complications were reversible and were managed by local treatment, with exception of cataract formation.
引用
- Pohlmann D, Vom Brocke GA, Winterhalter S, et al. Dexamethasone Inserts in Noninfectious Uveitis: A Single-Center Experience. Ophthalmology. 2018. PMID: 29459041. doi:10.1016/j.ophtha.2017.12.038
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。